Lennon David James 4
4 · Whitehawk Therapeutics, Inc. · Filed Mar 10, 2026
Research Summary
AI-generated summary of this filing
Whitehawk (WHWK) CEO David Lennon Sells Shares After RSU Vesting
What Happened
Lennon David James (CEO) had 16,250 restricted stock units (RSUs) convert to common shares on March 1, 2026. Following the vesting/conversion, a broker-assisted sale of 5,100 shares occurred on March 2, 2026 at $3.31 per share, generating $16,879 to satisfy tax withholding obligations.
Key Details
- Transactions reported: RSU conversion/exercise (code M) of 16,250 shares on 2026-03-01; broker-assisted open-market sale (code S) of 5,100 shares on 2026-03-02 at $3.31/share for $16,879.
- Filing date: Form 4 filed 2026-03-10 for transactions on Mar 1–2 (filed after the typical 2-business-day reporting window).
- Shares owned after the transactions: not specified in the provided filing excerpts.
- Footnotes: F1 explains each RSU equals a contingent right to one share; F2 confirms the sale was broker-assisted to satisfy tax withholding on RSU vesting; F3 outlines the RSU vesting schedule (25% after one year from Vesting Commencement Date of Mar 1, 2024, then 25% annually thereafter).
- Transaction types explained: M = conversion/exercise of derivative (RSU conversion to shares); S = sale (broker-assisted).
Context
This appears to be routine RSU vesting with a partial sale to cover tax withholding — common for equity compensation. The cash generated ($16.9k) and the size of the sale are relatively small; such withholding sales are generally administrative and not necessarily a signal about CEO sentiment.
Insider Transaction Report
Form 4
Lennon David James
DirectorCHIEF EXECUTIVE OFFICER
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-03-01+16,250→ 49,679 total - Sale
Common Stock
[F2]2026-03-02$3.31/sh−5,100$16,879→ 44,579 total - Exercise/Conversion
Restricted Stock Units
[F1][F3]2026-03-01−16,250→ 32,500 total→ Common Stock (16,250 underlying)
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
- [F2]Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
- [F3]Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean March 1, 2024.
Signature
/s/ Stephen Rodin, as Attorney-in-Fact|2026-03-10